Physician profile
Minsoo Kang
NPI 1780681569
$130,262.62
in general payments reported to CMS, 2019-2025
41 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $24K · 2021: $38K · 2022: $2,537 · 2023: $4,523 · 2024: $7,282 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $5,024 · Consulting Fee: $1,800 · Education: $305 · Travel and Lodging: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,031.25 |
| Food and Beverage | $5,023.91 |
| Consulting Fee | $1,800.00 |
| Education | $305.40 |
| Travel and Lodging | $135.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31,672.28 | 2019-2023 | Aimovig |
| Abbvie INC. | $26,679.68 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $25,211.12 | 2019-2025 | Ajovy, Austedo Xr |
| Lilly USA, LLC | $16,834.30 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Allergan, INC. | $11,546.89 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $5,764.06 | 2021 | |
| Pfizer INC. | $5,562.60 | 2023-2025 | |
| Lundbeck LLC | $4,402.78 | 2020-2025 | Vyepti, Rexulti |
| Tonix Medicines, INC. | $278.23 | 2024-2025 | Zembrace Symtouch |
| Livanova USA, INC. | $204.11 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Eisai INC. | $192.27 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $187.45 | 2023-2025 | Nuplazid |
| Sk Life Science, INC. | $181.37 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $176.97 | 2024-2025 | Crexont, Rytary |
| Otsuka America Pharmaceutical, INC. | $148.69 | 2024-2025 | Rexulti |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $132.40 | 2024-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $104.79 | 2024-2025 | |
| Upsher-Smith Laboratories LLC | $95.17 | 2019-2020 | |
| Impel Pharmaceuticals INC. | $89.10 | 2023 | Trudhesa |
| Emd Serono, INC. | $87.65 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82.72 | 2023-2024 | Hyqvia, Gammagard |
| Neurocrine Biosciences, INC. | $68.71 | 2020 | |
| Kyowa Kirin, INC. | $52.52 | 2020-2024 | Nourianz |
| Ucb, INC. | $52.51 | 2024 | Zilbrysq, Briviact |
| Acorda Therapeutics, INC | $44.61 | 2020-2024 | Inbrija, Ampyra |
| Catalyst Pharmaceuticals, INC. | $41.29 | 2024 | |
| Bioventus LLC | $41.11 | 2025 | Exogen Ultrasound Bone Healing System |
| Argenx US, INC. | $38.02 | 2024 | Vyvgart Hytrulo |
| Mdd US Operations, LLC | $36.71 | 2025 | Gocovri |
| Axsome Therapeutics, INC. | $36.24 | 2025 | Symbravo |
| Averitas Pharma INC. | $35.29 | 2025 | Qutenza |
| Novartis Pharmaceuticals Corporation | $23.96 | 2024 | |
| Endo USA, INC. | $23.50 | 2025 | Xiaflex |
| Alnylam Pharmaceuticals INC. | $20.64 | 2024 | Onpattro |
| Bausch Health US, LLC | $20.37 | 2019 | |
| Scilex Pharmaceuticals INC. | $16.46 | 2024 | |
| Alexion Pharmaceuticals, INC. | $16.41 | 2020 | |
| Sunovion Pharmaceuticals INC. | $15.81 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.05 | 2025 | Enhertu |
| Ge Healthcare | $14.65 | 2025 | |
| Merz Pharmaceuticals, LLC | $14.13 | 2024 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minsoo Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.